Obesity and chronic kidney disease
Conditions
Interventions
Eligible participants will be randomly assigned to 24 weeks treatment with
either semaglutide s.c. 2.4 mg once weekly (Semaglutide 3 mg/ml) or placebo.
The starting dose of semaglutide will be 0.24
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Age >= 18 years • Body Mass index >= 27 kg/m2 • Albuminuria >= 30 mg/g and = 25 ml/min/1.73m2 • Stable renal function prior to entry into the study defined as no more than 30% eGFR change in 3 months prior to enrolment • Signed Informed Consent
Exclusion criteria
Exclusion criteria: • Diagnosis with type 1 or type 2 Diabetes • Hba1c >= 6.5% at screening • Cardiovascular disease event in 3 months prior to enrollment • Treatment with GLP-1 RA 6.0 mIU/L or
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline to week 24 in first morning void urinary albumin:creatinine ratio (UACR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in: - eGFR (all subjects), - Iohexol measured GFR (46 subjects), - change in UACR and eGFR during wash-out from week 24 to 28, - body weight - hip circumference, - systolic/diastolic blood pressure, - extracellular fluid, - high sensitivity CRP. | — |
Countries
Netherlands
Outcome results
None listed